Skip to content
Companies

Medici Therapeutics

Tumor-infiltrating lymphocyte cell therapy for cancer

  • Boston, MA
  • Founded 2021
  • Biotech

Raised to date

$14.8M

of $14.8M offered across 1 Form D filing

Investors
11
Last filed
Dec 4, 2025

About

Medici Therapeutics, Inc. is a biotechnology company focused on developing advanced cancer treatments within the immunotherapy sector. The company's primary focus is on advancing tumor-infiltrating lymphocyte (TIL) therapies by leveraging novel insights into cancer immunology, particularly how cancer cells evade immune responses.

The company's distinct approach involves addressing a newly discovered mechanism of immune evasion where cancer cells sabotage T cells. Medici is developing methods to infuse TILs with healthy mitochondria to enhance their anti-tumor functionality and durability.

Funding

  • EquityFiled Dec 4, 2025Form D
    $14.8M/ $14.8M

Product

Tumor-Infiltrating Lymphocyte (TIL) Therapy

Adoptive Cell Therapy

The company is developing an adoptive cell therapy where a patient's own immune cells (lymphocytes) are extracted from their tumor, expanded in a laboratory setting, and then re-infused to attack the cancer. A key aspect of their development process is a novel enhancement technique that infuses the TILs with healthy mitochondria to counteract a mechanism cancer cells use to disable T cells, thereby improving therapeutic potency.

  • Autologous cell therapy using patient-derived immune cells
  • Ex-vivo expansion and enhancement of lymphocytes
  • Mitochondrial enhancement to boost T cell function

Built for

The primary target segment is cancer patients, specifically those with solid tumors who are candidates for advanced cellular immunotherapy.

People on file